Prophylactic High-Dose Gabapentin Reduces Opiate Use during Radiation Therapy for Head and Neck Squamous Cell...

Area of Science:

• Oncology
• Pharmacology
• Radiation Therapy

Background:

• Oral mucositis is a painful side effect of radiation therapy for head and neck squamous cell carcinoma (HNSCC).
• The effectiveness of prophylactic high-dose gabapentin in managing HNSCC-related oral mucositis is debated.
• Optimizing pain management during HNSCC treatment is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of prophylactic high-dose gabapentin in managing oral mucositis during radiation therapy for HNSCC.
• To compare opioid use and feeding tube placement in patients receiving different doses of gabapentin.
• To determine if high-dose gabapentin impacts the time to first opioid use.

Main Methods:

• Retrospective cohort analysis of primary HNSCC patients.
• Statistical comparison of baseline characteristics using Kruskal-Wallis and Fisher's exact tests.
• Multivariate regression models to assess time to first opioid use and feeding tube placement.

Main Results:

• 480 HNSCC patients were analyzed: 186 received 3600 mg gabapentin, 182 received 300-3200 mg, and 112 received none.
• The 3600 mg gabapentin group showed a significantly longer time to first opioid use (34.3 days) compared to no gabapentin (23.9 days) and lower-dose gabapentin (28.0 days).
• Opioid use during radiation therapy was significantly lower in the 3600 mg gabapentin group (31.8%) versus no gabapentin (60.1%) and lower-dose gabapentin (63.8%).

Conclusions:

• Prophylactic 3600 mg gabapentin is well-tolerated in HNSCC patients undergoing radiation therapy.
• High-dose gabapentin significantly reduced overall opioid requirements by half.
• The use of 3600 mg gabapentin delayed the onset of opioid use during treatment.